DSUI's 2025 report emphasizes advancements in urology through visionary leadership, innovation, and transformative technologies, including AI-powered diagnostics and interdisciplinary research. Dr.

The phase 3 PRESTO trial (NCT03009981) assessed combined androgen signaling blockade for a finite treatment period of 52 weeks in patients with high-risk biochemically relapsed prostate cancer. In ...

The KEYNOTE-905 trial showed significant survival benefits with enfortumab vedotin and pembrolizumab in muscle-invasive bladder cancer, suggesting a new standard for cisplatin-ineligible patients. The ...

The PR.21 study found no significant difference in rPFS between 177Lu-PSMA-617 and docetaxel in mCRPC patients. 177Lu-PSMA-617 showed a higher PSA response rate compared to docetaxel, with 36% vs 16% ...

An expert discusses how comparing the durability and treatment effects of newer minimally invasive therapies to gold standard transurethral resection of the prostate (TURP) or holmium laser ...

Scott Tagawa, MD, provides an overview of key findings from the PSMAddition study, evaluating 177Lu-PSMA-617 combined with ADT and ARPI in mHSPC. Data from the phase 3 PSMAddition trial (NCT04720157) ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...

Enzalutamide plus leuprolide significantly improves overall survival and metastasis-free survival in biochemically recurrent prostate cancer compared to leuprolide alone. Subgroup analysis revealed ...

Nivolumab significantly improves DFS, OS, and DSS in high-risk muscle-invasive urothelial carcinoma, especially in patients with PD-L1 expression ≥1%. The study's 5-year follow-up confirms nivolumab's ...

Lenvatinib plus everolimus reduced progression or death risk by 49% compared to cabozantinib in ccRCC patients post-PD-1 inhibitor progression. The combination showed a median progression-free ...

The combination of enfortumab vedotin and pembrolizumab improved event-free survival, overall survival, and pathological complete response in muscle-invasive bladder cancer patients ineligible for ...

Andrea Necchi, MD, shares key findings from the phase 2 GDFather-NEO trial, presented at ESMO 2025. Primary results from the phase 2 GDFather-NEO trial (NCT06059547) were presented at the 2025 ...